{"id":"NCT01114880","sponsor":"Abbott","briefTitle":"Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2010-09","completion":"2011-02","firstPosted":"2010-05-03","resultsPosted":"2011-11-04","lastUpdate":"2011-12-01"},"enrollment":344,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Adalimumab","type":"EXPERIMENTAL"}],"summary":"Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (NSAIDs)","primaryOutcome":{"measure":"Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria","timeFrame":"Week 12","effectByArm":[{"arm":"Adalimumab/Adalimumab","deltaMin":154,"sd":null},{"arm":"Placebo/Adalimumab","deltaMin":35,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":9,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":229},"commonTop":["Alanine aminotransferase increased","Upper respiratory tract infection","Aspartate aminotransferase increased","White blood cell count decreased","Blood triglycerides increased"]}}